CAPR Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings- Randomized, Double-Bl
CAPR Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings- Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit- Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--
CAPR Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings- Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit- Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--